Recombinant Human IFN-alpha-2B Protein

Description :
FAQ COA 已发表文献 Interferons (IFN) are a family of cytokines with potent antiviral, antiproliferative and immunomodulatory properties, classified based on their binding specificity to cell surface receptors. There are more than a dozen closely related IFN alpha subtypes found in both the human and mouse genome, each sharing about 80% amino acid (aa) sequence homology. There are several variants of human IFNA2, IFNA2a, IFNA2b and IFNA2c, which only differ by a few point mutations. The extracellular domain (ECD) of mature human IFNA2b shares 59% aa sequence identity with mouse IFNA2. The type I IFNs bind to the interferon alpha receptor (IFNAR), which consists of two subunits: IFNAR1 (alpha -subunit) and IFNAR2 (beta -subunit). While individual IFN alpha subtypes are known to display unique efficacies to viral protection, nothing is known about functions unique to IFNA2 in human physiology. However, IFNA2 has become the representative type I IFN subtype used in basic research and numerous clinical applications. Since being first approved for treatment of hairy cell leukemia in 1986, IFNA2b has been approved for the treatment of several malignancies including AIDS-related Kaposi’s sarcoma, malignant melanoma and chronic hepatitis B and C. More recently, human IFNA2b has been tested as a potential treatment for COVID-19. Product Properties Synonyms IFN-alpha 2bprotein Accession P01563 GeneID 3440 Source Yeast-derived Human IFN-2a protein,Cys24-Glu188(K23R). Molecular Weight Approximately 19.2 kDa AA Sequence CDLPQTHSLG SRRTLMLLAQ MRKISLFSCL KDRHDFGFPQ EEFGNQFQKA ETIPVLHEMI QQIFNLFSTK DSSAAWDETL LDKFYTELYQ QLNDLEACVI QGVGVTETPL MKEDSILAVR KYFQRITLYL KEKKYSPCAW EVVRAEIMRS FSLSTNLQES LRSKE Tag None Physical Appearance Sterile Filtered White lyophilized (freeze-dried) powder. Purity > 98% by SDS-PAGE and HPLC analyses. Biological Activity Fully biologically active when compared to standard. The specific activity determined by an anti-viral assay is no less than 1.6 108IU/mg. Endotoxin 0.1EU per 1g of the protein by the LAL method. Formulation Lyophilized from a 0.2 m filtered solution in PBS, pH 7.4, with 0.02 % Tween-20. Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1% BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at -20C. Further dilutions should be made in appropriate buffered solutions.